LABORATORIOS FARMACEUTICOS ROVI, S.A. Onderneming Laboratorios Farmaceuticos Rovi, S.A. Wiener Boerse
Aandelen
ROVI
ES0157261019
Farmaceutische producten
|
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 84,15 EUR | +1,02% |
|
-2,04% | +38,63% |
| 26/06 | Rovi ontvangt niet-bindende biedingen voor productieactiviteiten | RE |
| 08/05 | Laboratorios Farmaceuticos Rovi, S.A. rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024 | CI |
Vakgebied
- farmaceutische producten op contractbasis (49%);
- farmaceutische producten op recept (45%): bedoeld voor het voorkomen en behandelen van veneuze trombo-embolische aandoeningen, osteoporose na de menopauze, spierpijn, tand- en mondinfecties, angina, artrose, enz;
- diagnostische producten (6%): contrastproducten die gebruikt worden bij medische beeldvorming met magnetische resonantie, ultrageluid of röntgenstralen. De groep biedt ook ziekenhuisproducten en geneesmiddelen zonder recept.
De netto-omzet wordt per bron van inkomsten verdeeld tussen de verkoop van producten (50,6%), de verkoop van diensten (49,3%) en de verkoop van licenties (0,1%).
De netto-omzet is geografisch als volgt verdeeld: Spanje (33%), Europese Unie (17,3%), OESO-landen (45,9%) en overige (3,8%).
Aantal werknemers: 1 925
Verkoop per activiteit
| EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Marketing
50,7
%
| 414 | 50,6 % | 420 | 50,7 % | +1,47% |
Manufacturing
49,3
%
| 404 | 49,4 % | 409 | 49,3 % | +1,42% |
Verkoop per regio
| EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Organisation for Economic Co-operation and Development
45,9
%
| 377 | 46,1 % | 381 | 45,9 % | +1,09% |
Spain
33,0
%
| 264 | 32,3 % | 273 | 33,0 % | +3,44% |
European Union
17,3
%
| 137 | 16,7 % | 144 | 17,3 % | +5,20% |
Rest
3,8
%
| 40 | 4,9 % | 32 | 3,8 % | -21,18% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
| Chief Executive Officer | - | 01-01-94 | |
| Director of Finance/CFO | - | 01-01-00 | |
| Chief Tech/Sci/R&D Officer | - | - | |
| Director/Board Member | - | 01-01-95 | |
| Investor Relations Contact | - | 01-07-08 | |
| Sales & Marketing | - | 01-08-16 | |
| Sales & Marketing | - | - | |
| General Counsel | - | 01-06-07 | |
| Corporate Officer/Principal | - | - | |
| Comptroller/Controller/Auditor | - | 01-01-21 |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
| Director/Board Member | - | 01-01-95 | |
| Director of Finance/CFO | - | 01-01-00 | |
| Chief Executive Officer | - | 01-01-94 | |
| Director/Board Member | 57 | 01-01-19 | |
| Director/Board Member | - | 09-05-19 | |
| Director/Board Member | - | 10-05-22 | |
| Director/Board Member | - | 14-12-22 |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 1 | 54 016 157 | 19 274 107 ( 35,68 %) | 2 196 011 ( 4,065 %) | 35,68 % |
Participaties
| Naam | Aandelen | % | Totale waarde |
|---|---|---|---|
| 2 659 984 | 4.92% | 253 393 800 $ |
Bedrijfsgegevens
Laboratorios Farmaceúticos Rovi SA
Calle José Isbert, 2 Pozuelo de Alarcón
28223, Madrid
+34 91 021 30 00
http://www.rovi.es
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
Pan Química Farmacéutica SA
 Pan Química Farmacéutica SA Pharmaceuticals: MajorHealth Technology Part of Norbel Inversiones SL, Pan Química Farmacéutica SA is a Spanish company that manufactures pharmaceutical products. The company is located in Spain. |
Pharmaceuticals: Major
|
Rovi Contract Manufacturing SL
 Rovi Contract Manufacturing SL Pharmaceuticals: MajorHealth Technology Part of Norbel Inversiones SL, Rovi Contract Manufacturing SL is a Spanish company that has been researching and growing in the healthcare industry for 70 years. The company is located in Spain. The company offers prescription medical products manufactured or marketed by Laboratorios ROVI. The company is the ideal choice for pharmaceutical companies looking to outsource their manufacturing processes. The company also provides products for imaging diagnostics and other hospital products. |
Pharmaceuticals: Major
|
Frosst Ibérica SA
 Frosst Ibérica SA Pharmaceuticals: MajorHealth Technology Part of Norbel Inversiones SL, Frosst Ibérica SA is a leading pharmaceutical CMO. Our injectable and solid form products are manufactured in the metropolitan area in Alcala de Henares, Spain. We provide reliable aseptic filling for patients and are known for our expertise, constant dedication, and transparency in the field of contract manufacturing. Frosst Ibérica was acquired by ROVI Imaging SL from Merck & Co., Inc. on July 27, 2009 for $5.11 million. |
Pharmaceuticals: Major
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +55,32% | 815 mld. | |
| -6,75% | 352 mld. | |
| +13,56% | 314 mld. | |
| +10,68% | 303 mld. | |
| +16,57% | 242 mld. | |
| +2,04% | 224 mld. | |
| +13,31% | 218 mld. | |
| +8,48% | 168 mld. | |
| -2,81% | 159 mld. |
- Beurs
- Aandelen
- Koers ROVI
- Koers ROVI
- Onderneming Laboratorios Farmaceuticos Rovi, S.A.
